February 21st 2022

Published in Nature Communications: Mechanism of AT-527 presents as a promising research avenue against COVID-19

Published in Nature Communications: Mechanism of AT-527 presents as a promising research avenue against COVID-19

A research group including the CARE partner Aix-Marseille University investigated the guanosine analogue AT-527 (Bemnifobuvir) using high-resolution cryo-electromicroscopy. Once in cells, AT-527 is converted into AT-9010that presumably has a dual mechanism of action (1) at the level of the viral RNA-dependent RNA polymerase which enables incorporation into the viral RNA, stopping the synthesis of viral genomes, and (2) at the N-terminal domain of nsp12 where it inhibits the activity of nucleotidyltransferase, an enzyme that transfers a nucleotide from one structure to another. The dual mechanism represents a promising research avenue against COVID-19 and the detailed findings are published in Nature Communications.

To learn more, read the paper in Nature Communications: A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase